Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Bullboard Posts
Post by mrnormalon Sep 28, 2020 4:16pm
197 Views
Post# 31630467

News Coming

News Coming

Start of Phase 3 Trials any day now
https://clinicaltrials.gov/ct2/results?cond=&term=NCT04504734&cntry=&state=&city=&dist=

Official OTCQB Uplisting
https://www.otcmarkets.com/stock/RVVTF/overview

Q4 Pre-IND meeting with FDA for Psilocybin Treatment of Methamphetamine Use Disorder

Q4 Initial results from Phase 3 clinical study of Bucillamine in the treatment of COVID-19

Q4 Submit IND for Phase 2 clinical study of CBD in the treatment of
Autoimmune Hepatitis

Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)
Bullboard Posts